Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The COVID-19 pandemic has seen some extraordinary medical feats and achievements, which are being rightly celebrated. Researchers at Oxford University have been at the forefront of global efforts, including the first human trials of a COVID-19 vaccine, and the world’s biggest trial of potential COVID-19 treatments, RECOVERY. 

The Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial has recruited more than 10,000 patients in 176 hospitals in just two months - truly incredible figures for that timescale, making it the fastest ever recruiting individually randomised controlled trial. From conception to launch took just nine days! The trial is being co-led by Professor Peter Horby (Nuffield Department of Medicine) and Professor Martin Landray (Nuffield Department of Population Health), and is testing existing drugs, all with well-known side effects and confirmed safety, on hospital inpatients with suspected or confirmed COVID-19. 

Each participant is randomised via a secure 24/7 web-based system. Participants receive either the usual standard of hospital care, or one of four drugs - lopinavir-ritonavir, normally used to treat HIV, the steroid dexamethasone (or alternative corticosteroids), used in a wide range of conditions to reduce inflammation, hydroxychloroquine, which is mainly used as an anti-malarial drug and the antibiotic azithromycin. The study allows a second randomisation for patients with progressive COVID-19, who receive the usual standard of care or tocilizumab, an immunosuppressive drug. The researchers will be able to fairly compare each of the treatments with usual standard of care and work out which, if any, make a difference. The trial design is flexible and as new treatments are suggested or become available, it can be adapted to accommodate them. Indeed, azithromycin, tocilizumab and most recently, convalescent plasma (CP) arms were added after the trial began recruitment; CP is about to be offered on top of the main first line randomisation options. 

Read more on the Nuffield Department of Population Health website

Similar stories

Largest ever global study of tuberculosis identifies genetic causes of drug resistance

Using cutting-edge genomic sequencing techniques, researchers at the University of Oxford have identified almost all the genomic variation that gives people resistance to 13 of the most common tuberculosis (TB) drug treatments.

Peter Horby receives prestigious award for outstanding service to public health

The Faculty of Public Health (FPH) has awarded its prestigious Alwyn Smith Prize to Professor Sir Peter Horby (Nuffield Department of Medicine) for 2020/2021 in recognition of his outstanding service to public health as a global leader in epidemic science.

Six new Fellowships announced as part of Oxford-Bristol Myers Squibb Fellowships Programme

The Oxford - Bristol Myers Squibb (BMS) Fellowships Programme continued to demonstrate significant progress over the last year, despite the challenges associated with the global pandemic, including restricted lab access and work from home guidance. Today, we are pleased to announce six new Oxford-BMS Fellowships for 2021.

Researchers set out steps to address mental health effects of the pandemic on young people

Researchers have outlined 14 steps that schools, mental health services and policymakers can take to help children and young people whose mental health has been affected by the COVID-19 pandemic.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

Professor Trish Greenhalgh Highly Commended in the O²RB Excellence in Impact Awards 2021

Congratulations to Professor Trish Greenhalgh (Nuffield Department of Primary Care Health Sciences) who has been Highly Commended in the O²RB Excellence in Impact Awards 2021.